Published in

American Society for Clinical Pharmacology and Therapeutics, Clinical Pharmacology & Therapeutics, 5(93), p. 402-408

DOI: 10.1038/clpt.2013.2

Links

Tools

Export citation

Search in Google Scholar

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

Journal article published in 2013 by J. K. Hicks, J. J. Swen ORCID, C. F. Thorn, K. Sangkuhl, E. D. Kharasch, V. L. Ellingrod, T. C. Skaar, D. J. M??ller, D. J. Müller, A. Gaedigk, J. C. Stingl
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

White circle
Preprint: policy unclear
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes. Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites. These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites. Evidence from published literature is presented for CYP2D6 and CYP2C19 genotype-directed dosing of tricyclic antidepressants.Clinical Pharmacology & Therapeutics (2013); advance online publication 13 March 2013. doi:10.1038/clpt.2013.2.